COGNICURRENT

Feb 4 • 10:51 UTC • 🇬🇧 UK • Guardian

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk, the maker of Wegovy and Ozempic, expects a significant revenue decline this year due to competition, patent expirations, and price reductions influenced by Donald Trump's policies.

#novo nordisk #wegovy #ozempic #trump #pharmaceuticals

Read Original Back to Feed

📡 Similar Coverage

🇪🇸 Spain Feb 4 • 10:02 UTC

Novo Nordisk's shares plummet amid strong sales forecast drop for Ozempic and Wegovy this year

El País

🇪🇪 Estonia Feb 25 • 09:55 UTC

The prices of Ozempic and Wegovy will drop by up to half – but not everyone will benefit

Postimees

🇪🇸 Spain Feb 4 • 12:32 UTC

Novo Nordisk crashes in stock market after lowering sales forecast for Ozempic, its star drug

elDiario.es

🇩🇰 Denmark Feb 24 • 13:10 UTC

Novo Nordisk Reduces List Price of Wegovy in the USA by Half

Politiken

🇧🇷 Brazil Mar 3 • 14:21 UTC

17 days before the patent expires, pharmaceutical company lowers the price of Rybelsus and offers free dose of Wegovy

Folha (PT)

🇪🇸 Spain Jan 15 • 15:14 UTC

A generic Ozempic for 15 euros per month or how to revolutionize the obesity drug market

El País